{"product_id":"admedsol-bcg-matrix","title":"Advanced Medical Solutions Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Advanced Medical Solutions Group BCG Matrix teases how its product lines stack up—where market leaders sit, which offerings need cash, and which could be phased out as the market shifts. This snapshot highlights growth vs share tensions and points to strategic bets, but it’s only the surface. Buy the full BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and ready-to-use Word and Excel files that make investment and portfolio decisions fast and defensible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquiBand tissue adhesives (OR\/ER closure)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquiBand sits as a Star: it commands a leading share in the growing shift from sutures and staples to tissue adhesives, driven by strong surgeon pull; sustained adoption still requires targeted education, randomized trials and dedicated theatre reps. The product line is cash-hungry in the near term, but with clear scale pathways—retaining share should convert LiquiBand into a significant cash engine as the market matures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntimicrobial infection-prevention dressings (silver, biofilm-focused)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAntimicrobial infection-prevention dressings (silver, biofilm-focused) ride strong hospital-led demand to cut SSIs and readmissions, addressing SSIs that add roughly 7 extra hospital days and up to $20,000 per case in the US. Global guideline pushes from WHO and CDC continue to drive adoption, supporting market growth (wound care markets growing mid-single digits CAGR). Ongoing clinical evidence generation and field sales support soak cash during scale-up; maintain share and this Star can move to cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkin adhesive applicators tailored for high-throughput urgent care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRapid adoption in urgent care is driven by speed and simplicity, and AMS’s fit-for-purpose skin adhesive applicators are positioned as Stars in the BCG matrix for meeting throughput needs. Market growth is brisk as sites push higher patient throughput and lower cost-per-closure, but heavy sampling, on-site training, and field support remain necessary. Consistent tender wins sustain deployment momentum and the commercial flywheel continues to turn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced foams with differentiated exudate management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced foams with differentiated exudate management target the premium segment of a growing advanced wound care market valued at about USD 12.5 billion in 2024 with ~5.6% CAGR, where clinical performance drives purchasing decisions; AMS holds meaningful share and benefits from clinical spec-in but still invests in marketing and distributor enablement. To maintain outcomes and scale towards cash‑cow margins, continued clinical evidence and supply scale are required.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket 2024: USD 12.5B, CAGR ~5.6%\u003c\/li\u003e\n\u003cli\u003eAMS: meaningful share, clinical spec-in advantage\u003c\/li\u003e\n\u003cli\u003eCosts: ongoing marketing \u0026amp; distributor enablement\u003c\/li\u003e\n\u003cli\u003ePriority: scale outcomes to convert to cash cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdhesive alternatives to sutures in minimally invasive procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinician preference is shifting toward adhesives in minimally invasive procedures, with procurement-driven adoption contributing to a reported 10% market growth in 2024; AMS, with double-digit revenue growth in its adhesives portfolio, has credible solutions and expanding indications across laparoscopy and endoscopy.\u003c\/p\u003e\n\u003cp\u003eAMS must accelerate KOL development and procedural training to lock in share; invest now to cement leadership before adoption curve flattens.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth 2024: ~10%\u003c\/li\u003e\n\u003cli\u003eAMS adhesives revenue: double-digit growth 2024\u003c\/li\u003e\n\u003cli\u003ePriority: KOLs \u0026amp; training\u003c\/li\u003e\n\u003cli\u003eAction: immediate investment to secure share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntimicrobial dressings, urgent-care adhesives and foams: invest now to scale margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLiquiBand, antimicrobial dressings, urgent-care adhesives and advanced foams are Stars: high share in expanding markets (advanced wound care USD 12.5B 2024, adhesives +10% 2024). They need near-term cash for trials, field sales and training but can become cash cows as scale lowers unit costs and margins improve.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 market\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eAMS position\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquiBand\u003c\/td\u003e\n\u003ctd\u003eAdhesives +10% (2024)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eLeading share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntimicrobial dressings\u003c\/td\u003e\n\u003ctd\u003eSSI cost ~USD20k\/case\u003c\/td\u003e\n\u003ctd\u003eMid\u003c\/td\u003e\n\u003ctd\u003eStrong hospital demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrgent-care adhesives\u003c\/td\u003e\n\u003ctd\u003eHigh throughput sites\u003c\/td\u003e\n\u003ctd\u003eBrisk\u003c\/td\u003e\n\u003ctd\u003eRapid adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced foams\u003c\/td\u003e\n\u003ctd\u003eUSD12.5B (2024)\u003c\/td\u003e\n\u003ctd\u003e~5.6% CAGR\u003c\/td\u003e\n\u003ctd\u003eMeaningful share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix review of Advanced Medical Solutions - flags Stars to invest, Cash Cows to harvest, Question Marks to test, and Dogs to divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix for Advanced Medical Solutions Group — highlights where to invest or cut, C-level ready.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore foam and alginate dressings (standard lines)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCore foam and alginate dressings are mature, spec’d-in across hospitals and community settings with steady volumes and high channel share; the advanced wound-care category showed modest growth of roughly 3–4% in 2024. Low promotional spend is required, so supply reliability and cost control drive margin retention. These lines generate predictable cash flow for AMS while the team defends formulary positions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate-label\/OEM wound care manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrivate-label\/OEM wound care at Advanced Medical Solutions generates stable, contract-driven reorders with tight operations and high share-of-customer; growth is low single-digit while margins improve with scale and ongoing efficiency programs, so prioritize service levels and harvest cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-op dressings used across routine surgeries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePost-op dressings are everyday SKUs with entrenched demand and minimal switching; AMS holds leading placement in hospitals and ambulatory centers, capturing steady volume despite the market's low single-digit growth in 2024. Limited marketing beyond account management is needed, keeping OPEX low. Prioritize manufacturing optimization to improve gross margins. Let the product line generate predictable cash flow for reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished ER\/primary care closure SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished ER\/primary care closure SKUs are known, trusted and reordered on autopilot across many sites; AMS reported consistent unit volumes in 2024 while the category experienced flat-to-low growth (0–2% in 2024) and AMS maintained a leading share near 25–30%. Light-touch promotion sustains low churn; priority is maximizing margins and accelerating inventory turns to free working capital.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKnown SKU\u003c\/li\u003e\n\u003cli\u003eFlat market 0–2% (2024)\u003c\/li\u003e\n\u003cli\u003eAMS share ~25–30%\u003c\/li\u003e\n\u003cli\u003eLow churn via light promotion\u003c\/li\u003e\n\u003cli\u003eFocus: margins \u0026amp; inventory turns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLongstanding EMEA tender positions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLongstanding EMEA framework agreements deliver recurring volumes and predictable low-single-digit market growth in 2024, keeping tender price pressure steady; operational excellence sustained above-industry margins through cost control and scale, while compliance and service continuity remain critical to retain contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring volumes: locked-in frameworks\u003c\/li\u003e\n\u003cli\u003eGrowth: low single-digit (2024)\u003c\/li\u003e\n\u003cli\u003eMargin driver: operational excellence\u003c\/li\u003e\n\u003cli\u003eRisk control: compliance \u0026amp; service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefend core foam, harvest private-label cash, optimize post-op manufacturing \u0026amp; margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore foam\/alginate: mature, steady volumes (growth 3–4% in 2024), defend formulary; Private-label\/OEM: contract-stable, low single-digit growth, harvest cash; Post-op: entrenched SKUs, low single-digit growth, optimize manufacturing; ER closures: flat 0–2% (2024), AMS share ~25–30%, focus margins\/inventory; EMEA frameworks: recurring low-single-digit growth, operational excellence vital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 growth\u003c\/th\u003e\n\u003cth\u003eAMS share\u003c\/th\u003e\n\u003cth\u003ePriority\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore foam\/alginate\u003c\/td\u003e\n\u003ctd\u003e3–4%\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eDefend formulary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate-label\u003c\/td\u003e\n\u003ctd\u003eLow single-digit\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eHarvest cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-op\u003c\/td\u003e\n\u003ctd\u003eLow single-digit\u003c\/td\u003e\n\u003ctd\u003eLeading\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eER closures\u003c\/td\u003e\n\u003ctd\u003e0–2%\u003c\/td\u003e\n\u003ctd\u003e25–30%\u003c\/td\u003e\n\u003ctd\u003eMargins\/inventory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMEA frameworks\u003c\/td\u003e\n\u003ctd\u003eLow single-digit\u003c\/td\u003e\n\u003ctd\u003eContracted\u003c\/td\u003e\n\u003ctd\u003eOperational excellence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAdvanced Medical Solutions Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing for Advanced Medical Solutions Group's BCG Matrix is the exact document you'll receive after purchase. No watermarks, no placeholder text—just a fully formatted, strategy-ready report. It mirrors the final downloadable file so there are no surprises. Ready to edit, print, or present to stakeholders immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164108927353,"sku":"admedsol-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/admedsol-bcg-matrix.png?v=1762726022","url":"https:\/\/portersfiveforce.com\/products\/admedsol-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}